Sixty-six (33.2%) patients were classified as luminal A, 55 (27.6%) were luminal B, 26 (13.1%) were HER2-positive, and 52 (26.1%) had triple-negative breast cancer. Here, ERBB2 is linked to triple-negative breast carcinoma.